adagrasib: Clinical Trials

22 trials of adagrasib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated, 6 completed, 4 recruiting, 2 active not recruiting. 22 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 122Terminated 7, Completed 6, Recruiting 4, Active not recruiting 2, Withdrawn 2, Unknown 1
Phase 25Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1

Follow adagrasib: new trials by email Literature Review of adagrasib trials Research Report on adagrasib

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
Adagrasib - Healthy Participants
Phase 1CompletedMirati Therapeutics Inc.102026-08-052026-09-28
Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial
Adagrasib, Iza-bren - Non-small Cell Lung Cancer
Phase 1RecruitingM.D. Anderson Cancer Center182026-05-152026-08-11
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
BMS-986488, Adagrasib, Cetuximab - Advanced Malignant Tumors
Phase 1RecruitingBristol-Myers Squibb4372025-03-252026-07-29
Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets
Adagrasib - Healthy Volunteers
Phase 1CompletedMirati Therapeutics Inc.1602025-02-042025-07-16
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Cetuximab, Cemiplimab, Adagrasib - Metastatic Colorectal Cancer, KRAS G12C Mutations
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center312024-08-282026-06-26
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Adagrasib, Olaparib - Advanced Solid Tumor, Non-small Cell Lung Cancers
Phase 1TerminatedM.D. Anderson Cancer Center12024-01-302026-04-09
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
INCB099280, adagrasib - Advanced Solid Tumors
Phase 1TerminatedIncyte Corporation62023-12-282026-09-08
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
MRTX849, Irinotecan, Cetuximab - Colon Cancer, Colorectal Cancer
Phase 1Active not recruitingM.D. Anderson Cancer Center242023-12-062026-08-14
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
BMS-986466, Adagrasib, Cetuximab - Advanced Solid Tumors
Phase 1 / Phase 2TerminatedBristol-Myers Squibb52023-11-092025-07-22
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Darlifarnib, Cabozantinib, Adagrasib - Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC)
Phase 1RecruitingKura Oncology, Inc.3002023-10-182026-10-14
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Adagrasib, nab-Sirolimus - Solid Tumor, Adult, NSCLC
Phase 1TerminatedMirati Therapeutics Inc.62023-08-072025-04-25
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
Adagrasib, Eltrombopag + adagrasib - Healthy Adults
Phase 1CompletedMirati Therapeutics Inc.162023-06-292024-03-13
Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
MRTX849 - Metastatic Pancreatic Cancer
Phase 1WithdrawnM.D. Anderson Cancer Center2023-05-032025-07-25
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
Durvalumab, Adagrasib - Lung Cancer, Gastro-intestinal Cancer
Phase 1WithdrawnM.D. Anderson Cancer Center2023-04-252024-01-23
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
MRTX0902, MRTX849 - Solid Tumor, Advanced Solid Tumor
Phase 1TerminatedMirati Therapeutics Inc.642022-12-022026-02-19
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
avutometinib (VS-6766) and adagrasib - Non Small Cell Lung Cancer, KRAS Activating Mutation
Phase 1 / Phase 2CompletedVerastem, Inc.122022-08-012026-07-02
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
MRTX849 - Advanced or Metastatic Solid Tumor
Phase 1UnknownZai Lab (Shanghai) Co., Ltd.222022-05-302023-02-27
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
MRTX849, Palbociclib - Advanced Solid Tumor
Phase 1CompletedMirati Therapeutics Inc.112022-01-202025-02-11
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
MRTX849, BI 1701963 - Advanced Cancer, Metastatic Cancer
Phase 1TerminatedMirati Therapeutics Inc.72021-07-282024-12-16
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Vociprotafib, Pembrolizumab, Adagrasib - Metastatic Neoplasm
Phase 1 / Phase 2TerminatedSanofi652020-06-092025-05-29

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (9)  ·  Colorectal Neoplasms (9)  ·  Neoplasm Metastasis (7)  ·  Neoplasms (6)  ·  Colonic Neoplasms (5)  ·  Pancreatic Neoplasms (4)  ·  Lung Neoplasms (3)  ·  Carcinoma, Renal Cell (2)  ·  Biliary Tract Neoplasms (1)  ·  Kidney Neoplasms (1)

Sponsors

Mirati Therapeutics Inc. (9)  ·  M.D. Anderson Cancer Center (6)  ·  Bristol-Myers Squibb (2)  ·  Incyte Corporation (1)  ·  Kura Oncology, Inc. (1)  ·  Sanofi (1)  ·  Verastem, Inc. (1)  ·  Zai Lab (Shanghai) Co., Ltd. (1)

Countries

United States (21)  ·  Australia (3)  ·  Spain (3)  ·  France (2)  ·  Italy (2)  ·  Puerto Rico (2)  ·  Argentina (1)  ·  Canada (1)  ·  Chile (1)  ·  China (1)  ·  Finland (1)  ·  Germany (1)  ·  Israel (1)  ·  South Korea (1)  ·  Taiwan (1)

Top investigators

Christine Parseghian, MD (1)  ·  Dan Zhao, MD (1)  ·  David S. Hong, MD (1)  ·  MD Verastem (1)  ·  Marcelo V Negrao, MD (1)  ·  Marcelo V. Negrao, MD (1)  ·  Richard Chao, MD (1)  ·  Timothy Yap, MD (1)

Results publications

PMID 34161704, PMID 35167329, PMID 35404402, PMID 35658005, PMID 36546659, PMID 37099736, PMID 37327468, PMID 38579193

NIH funding

2023 (2)